Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Capricor Therapeutics (CAPR) Notes Payables (2020 - 2021)

Capricor Therapeutics has reported Notes Payables over the past 3 years, most recently at $282691.0 for Q1 2021.

  • Quarterly results put Notes Payables at $282691.0 for Q1 2021, changed N/A from a year ago — trailing twelve months through Mar 2021 was $282691.0 (changed N/A YoY), and the annual figure for FY2020 was $246689.0, changed.
  • Notes Payables for Q1 2021 was $282691.0 at Capricor Therapeutics, up from $246689.0 in the prior quarter.
  • Over the last five years, Notes Payables for CAPR hit a ceiling of $282691.0 in Q1 2021 and a floor of $139927.0 in Q2 2020.